Remestemcel-l clinical and potency studies presented at premier meeting of transplantation research and therapy

New york, feb. 16, 2023 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that two studies on the remestemcel-l development program for the treatment of children with steroid-refractory acute graft versus host disease (sr-agvhd) were selected by peer review to be presented at the 2023 tandem meetings of the american society for transplantation and cellular therapy (astct) and the center for blood and marrow transplant research (cibmtr), taking place february 15-19 in orlando, florida.
MESO Ratings Summary
MESO Quant Ranking